Trials / Recruiting
RecruitingNCT06551142
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of GSK5764227 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 590 (estimated)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this study is to assess the safety, tolerability, clinical activity and pharmacokinetics of GSK5764227. The study will also see how the levels of GSK5764227 will change over time at different dose amounts when administered alone and in combination with other medicines like carboplatin, cisplatin, atezolizumab, pembrolizumab, durvalumab, bevacizumab, cetuximab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | GSK5764227 | GSK5764227 will be administered |
| DRUG | Cisplatin | Cisplatin will be administered |
| DRUG | Carboplatin | Carboplatin will be administered |
| BIOLOGICAL | Atezolizumab | Atezolizumab will be administered |
| BIOLOGICAL | Pembrolizumab | Pembrolizumab will be administered |
| BIOLOGICAL | Durvalumab | Durvalumab will be administered |
| BIOLOGICAL | Cetuximab | Cetuximab will be administered |
| BIOLOGICAL | Bevacizumab | Bevacizumab will be administered |
Timeline
- Start date
- 2024-09-30
- Primary completion
- 2026-09-24
- Completion
- 2027-05-19
- First posted
- 2024-08-13
- Last updated
- 2025-12-18
Locations
53 sites across 11 countries: United States, Argentina, Canada, France, Italy, Japan, Panama, South Korea, Spain, Taiwan, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06551142. Inclusion in this directory is not an endorsement.